Versant Venture Management, LLC
Versant Voyageurs III, L.P.
Late investment period: first sale Oct 2022, per Form D (fund age approximates vintage)
- Vintage
- 2022
- Fund size
- $300.18M to $309.95M (Form D and SEC adviser filing)
- Stages
- Not stated
- Sectors
- Biotech
- Regions
- Not stated
01 · Thesis
Versant builds biotechnology companies with academic founders through in-house discovery engines of multi-disciplinary scientists working in state-of-the-art laboratory facilities. Portfolio examples include clinical programs in pulmonary hypertension and obesity.Inferred from the firm's website and portfolio companies
02 · Initial check
$3M to $5.17M (estimated from fund size)
Estimated from Form D and SEC adviser filing
03 · Who to approach
Named on this fund's Form D
- Carlo Rizzuto, Managing Director of the Ultimate General Partner
- Bradley Bolzon, Managing Director of the Ultimate General Partner
- Jerel Davis, Managing Director of the Ultimate General Partner
- Alex Mayweg, Managing Director of the Ultimate General Partner
- Tom Woiwode, Managing Director
- Clare Ozawa, Managing Director of the Ultimate General Partner
04 · Deals
No deals attributed to this fund yet.
05 · Evidence
Firm-wideVersant builds biotechnology companies with academic founders through in-house discovery engines of multi-disciplinary scientists.
Versant’s Discovery Engines comprise in-house teams of multi-disciplinary scientists working in state-of-the-art laboratory facilities to enable the launch of novel biotechnology companies with academic founders.
http://www.versantventures.com/
06 · Sources
Last verified: Oct 28, 2026